Clinical trial
An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat…
NCT00116662 · Graceway Pharmaceuticals, LLC, Industry · Completed
Key facts
| NCT number | NCT00116662 |
|---|---|
| Title | An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects |
| Official title | A Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times Per Week for up to 12 Weeks for the Treatment of Common Warts in Pediatric Subjects |
| Lead sponsor | Graceway Pharmaceuticals, LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Warts |
| Intervention type | Drug |
| Interventions | Resiquimod |
| Enrollment | 84 |
| Start date | Mar 1, 2005 |
| First posted | Jul 1, 2005 |
| Last update posted | Feb 19, 2007 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: